An observational study evaluating long-acting injectable cabotegravir (CAB-LA; APRETUDE) healthcare provider and user experience and utilization for pre-exposure prophylaxis (PrEP) against HIV in Canada (223857)

31/10/2025
11/12/2025
EU PAS number:
EUPAS1000000801
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

HIV Apretude KAB survey and PSP analysis_Protocol_ FINAL-Anonymised.pdf

English (1.88 MB - PDF) View document
Study results
Study report
Other information